Envista Holdings Co. (NYSE:NVST) Receives $25.86 Average PT from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have earned an average recommendation of “Reduce” from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $25.86.

A number of research analysts have weighed in on the company. Leerink Partnrs restated an “underperform” rating on shares of Envista in a report on Monday, February 26th. SVB Leerink initiated coverage on shares of Envista in a research note on Monday, February 26th. They set an “underperform” rating and a $19.00 price objective for the company. Robert W. Baird decreased their target price on shares of Envista from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, May 2nd. Jefferies Financial Group lowered Envista from a “buy” rating to a “hold” rating and dropped their price target for the company from $30.00 to $23.00 in a research report on Friday, February 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Thursday, May 2nd.

Envista Stock Down 3.5 %

NVST stock opened at $17.97 on Friday. The stock has a market capitalization of $3.09 billion, a P/E ratio of -24.96, a P/E/G ratio of 14.62 and a beta of 1.35. Envista has a 52 week low of $17.83 and a 52 week high of $36.14. The firm has a 50-day simple moving average of $19.97 and a 200-day simple moving average of $22.04. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.34.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, May 1st. The company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). The firm had revenue of $623.60 million for the quarter, compared to analyst estimates of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. Envista’s revenue was down .6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.38 EPS. Equities analysts forecast that Envista will post 1.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVST. Headinvest LLC purchased a new stake in shares of Envista during the 3rd quarter worth $28,000. Fifth Third Bancorp boosted its position in shares of Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after acquiring an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Envista during the 3rd quarter worth about $47,000. Signaturefd LLC increased its holdings in shares of Envista by 1,297.9% in the 4th quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock valued at $63,000 after acquiring an additional 2,427 shares during the last quarter. Finally, Covestor Ltd raised its position in shares of Envista by 33.9% during the 3rd quarter. Covestor Ltd now owns 2,462 shares of the company’s stock worth $69,000 after acquiring an additional 624 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.